Aclaris Therapeutics, Inc. (ACRS)

Market Cap	282.87M
Revenue (ttm)	27.08M
Net Income (ttm)	-37.00M
Shares Out	71.43M
EPS (ttm)	-0.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,737,712
Open	4.440
Previous Close	4.590
Day's Range	3.670 - 4.440
52-Week Range	0.770 - 4.440
Beta	0.12
Analysts	Buy
Price Target	7.20 (+81.82%)
Earnings Date	Nov 6, 2024

About ACRS

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials f...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 7, 2015
• Employees: 91
• Stock Exchange: NASDAQ
• Ticker Symbol: ACRS
• Website: https://www.aclaristx.com

Financial Performance

In 2023, Aclaris Therapeutics's revenue was $31.25 million, an increase of 5.03% compared to the previous year's $29.75 million. Losses were -$88.48 million, 1.81% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for ACRS stock is "Buy." The 12-month stock price forecast is $7.2, which is an increase of 81.82% from the latest price.

Price Target

$7.2

(81.82% upside)

Analyst Consensus: Buy